Standard BioTools Inc. Cost of Revenue
Standard BioTools Inc. (LAB) reported Cost of Revenue of $9.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Standard BioTools Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $9.57M, a 14.06% decline year-over-year.
- Standard BioTools Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $9.84M, a 7.25% increase year-over-year.
- Standard BioTools Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $12.41M, a 7.50% decline year-over-year.
- Standard BioTools Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $10.07M, a 1.08% increase year-over-year.
- Standard BioTools Inc. cost of goods and services sold for fiscal 2025 was $42.79M, a 7.23% decline from fiscal 2024.
- Standard BioTools Inc. cost of goods and services sold for fiscal 2024 was $46.13M, a 17.47% decline from fiscal 2023.
- Standard BioTools Inc. cost of goods and services sold for fiscal 2023 was $55.89M, a 8.22% decline from fiscal 2022.
- Standard BioTools Inc. cost of goods and services sold for fiscal 2022 was $60.90M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.57M 10-Q · filed 2026-08-05 | $19.41M 10-Q · filed 2026-08-05 | $31.82M derived: sum of 3 quarters · filed 2026-08-05 | $41.89M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $9.84M 10-Q · filed 2026-05-06 | $22.25M derived: sum of 2 quarters · filed 2026-05-06 | $32.32M derived: sum of 3 quarters · filed 2026-05-06 | $43.45M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $12.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $22.48M derived: sum of 2 quarters · filed 2026-03-16 | $33.62M derived: sum of 3 quarters · filed 2026-08-05 | $42.79M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $10.07M 10-Q · filed 2025-11-04 | $21.20M derived: sum of 2 quarters · filed 2026-08-05 | $30.38M 10-Q · filed 2025-11-04 | $43.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $11.13M 10-Q · filed 2026-08-05 | $20.31M 10-Q · filed 2026-08-05 | $33.73M derived: sum of 3 quarters · filed 2026-08-05 | $43.69M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $9.17M 10-Q · filed 2026-05-06 | $21.05M 10-Q · filed 2025-05-06 | $22.59M derived: sum of 2 quarters · filed 2026-05-06 | $32.55M derived: sum of 3 quarters · filed 2026-05-06 | $44.67M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $23.38M derived: sum of 2 quarters · filed 2026-03-16 | $35.50M derived: sum of 3 quarters · filed 2026-03-16 | $46.13M 10-K · filed 2026-03-16 | $90.17M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $9.96M 10-Q · filed 2025-11-04 | $21.71M 10-Q · filed 2024-11-06 | $22.08M derived: sum of 2 quarters · filed 2025-11-04 | $32.70M 10-Q · filed 2025-11-04 | $65.36M 10-Q · filed 2024-11-06 | $58.26M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-06-30 | $12.12M 10-Q · filed 2025-08-15 | $22.30M 10-Q · filed 2024-08-06 | $22.75M 10-Q · filed 2025-08-15 | $43.65M 10-Q · filed 2024-08-06 | $48.30M derived: sum of 3 quarters · filed 2026-03-16 | $62.51M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-03-31 | $21.35M 10-Q · filed 2025-05-06 | $36.18M derived: sum of 2 quarters · filed 2026-03-16 | $50.40M derived: sum of 3 quarters · filed 2026-03-16 | $64.46M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.04M derived: sum of 2 quarters · filed 2026-03-16 | $43.11M derived: sum of 3 quarters · filed 2026-03-16 | $55.89M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $14.21M 10-Q · filed 2024-11-06 | $28.28M derived: sum of 2 quarters · filed 2024-11-06 | $41.06M 10-Q · filed 2024-11-06 | $56.97M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $14.06M 10-Q · filed 2024-08-06 | $26.90M 10-Q · filed 2024-08-06 | $26.85M 10-Q · filed 2023-08-08 | $42.76M derived: sum of 3 quarters · filed 2025-03-11 | $59.18M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-03-31 | $12.84M 10-Q · filed 2024-05-09 | $28.69M derived: sum of 2 quarters · filed 2025-03-11 | $45.12M derived: sum of 3 quarters · filed 2025-03-11 | $59.47M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | $15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $32.28M derived: sum of 2 quarters · filed 2025-03-11 | $46.63M derived: sum of 3 quarters · filed 2025-03-11 | $60.90M 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $16.43M 10-Q · filed 2023-11-07 | $30.78M derived: sum of 2 quarters · filed 2023-11-07 | $45.04M 10-Q · filed 2023-11-07 | |||||
| 2022-06-30 | $14.35M 10-Q · filed 2023-08-08 | $28.62M 10-Q · filed 2023-08-08 | ||||||
| 2019-12-31 | $14.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $27.01M derived: sum of 2 quarters · filed 2020-02-27 | $39.84M derived: sum of 3 quarters · filed 2020-02-27 | $52.96M 10-K · filed 2020-02-27 | ||||
| 2019-09-30 | $12.46M 10-Q · filed 2019-11-08 | $25.29M derived: sum of 2 quarters · filed 2019-11-08 | $38.41M 10-Q · filed 2019-11-08 | $51.93M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2019-06-30 | $12.83M 10-Q · filed 2019-08-07 | $25.95M 10-Q · filed 2019-08-07 | $39.47M derived: sum of 3 quarters · filed 2020-02-27 | $52.61M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2019-03-31 | $13.12M 10-Q · filed 2019-05-07 | $26.64M derived: sum of 2 quarters · filed 2020-02-27 | $39.78M derived: sum of 3 quarters · filed 2020-02-27 | $52.62M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-12-31 | $13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $26.66M derived: sum of 2 quarters · filed 2020-02-27 | $39.49M derived: sum of 3 quarters · filed 2020-02-27 | $51.31M 10-K · filed 2020-02-27 | ||||
| 2018-09-30 | $13.14M 10-Q · filed 2019-11-08 | $25.98M derived: sum of 2 quarters · filed 2019-11-08 | $37.80M 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $12.84M 10-Q · filed 2019-08-07 | $24.66M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | $11.82M 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $49.95M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $46.01M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |